Holen Sie sich die Stockscreener-App
21.28
1.26%
0.265
Schlusskurs vom Vortag:
$21.02
Offen:
$21.22
24-Stunden-Volumen:
1.00M
Relative Volume:
0.82
Marktkapitalisierung:
$2.60B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
18.03
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
-1.34%
1M Leistung:
-2.30%
6M Leistung:
-8.24%
1J Leistung:
+23.94%
1-Tages-Spanne:
$21.14
$21.64
1-Wochen-Bereich:
$20.72
$21.64
52-Wochen-Spanne:
$15.34
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.28 | 2.56B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
What is the dividend policy of Catalyst Pharmaceuticals Inc. stockAdvanced Screener Data Feed To Watch Now - jammulinksnews.com
What are analysts’ price targets for Catalyst Pharmaceuticals Inc. in the next 12 monthsStock Market Picks With High Returns - jammulinksnews.com
How many analysts rate Catalyst Pharmaceuticals Inc. as a “Buy”Free Stock Review Backed By Experts - jammulinksnews.com
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Can Traders Expect Breakout From Catalyst Pharmaceuticals Inc. This WeekSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen enviable returns of 404% over the past five years - Yahoo Finance
What makes Catalyst Pharmaceuticals Inc. stock price move sharplyReal Time Outlook With High Returns - jammulinksnews.com
What are the latest earnings results for Catalyst Pharmaceuticals Inc.Free Stock Market Forecast Reports - jammulinksnews.com
What catalysts could drive Catalyst Pharmaceuticals Inc. stock higher in 2025Rapid-fire capital growth - jammulinksnews.com
When is Catalyst Pharmaceuticals Inc. stock expected to show significant growthRetirement Planning Updates For Consistent Profits - jammulinksnews.com
Is Catalyst Pharmaceuticals Inc. stock overvalued or undervaluedRemarkable growth - jammulinksnews.com
Why is Catalyst Pharmaceuticals Inc. stock attracting strong analyst attentionExpert guidance for superior capital growth - jammulinksnews.com
What are the technical indicators suggesting about Catalyst Pharmaceuticals Inc.Capitalize on market trends early - jammulinksnews.com
How does Catalyst Pharmaceuticals Inc. compare to its industry peersAchieve superior returns with professional insights - jammulinksnews.com
What analysts say about Catalyst Pharmaceuticals Inc. stockExtraordinary profit generation - PrintWeekIndia
Is Catalyst Pharmaceuticals Inc. a good long term investmentMassive stock growth - Autocar Professional
Will Catalyst Pharmaceuticals Inc. stock split in the near futureSpectacular growth rates - jammulinksnews.com
What makes Catalyst Pharmaceuticals Inc. stock attractive to long term investorsRecord-breaking gains - jammulinksnews.com
What drives Catalyst Pharmaceuticals Inc. stock priceLightning-fast capital gains - Autocar Professional
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance
Zacks.com featured highlights Catalyst Pharmaceuticals, SunOpta, Gambling.com and Orion Group - sharewise.com
Catalyst Pharmaceuticals Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewswire
Catalyst Pharmaceuticals Scheduled to Release Q2 2025 Financial Results on August 6, 2025 - Nasdaq
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):